omeprazole + pantoprazole (University of Florida)

Omeprazole + pantoprazole refers to a therapeutic regimen or comparative study involving two proton pump inhibitors (PPIs), primarily investigated by the University of Florida in the context of preventing gastrointestinal hemorrhage. The specific research focus (NCT01124240) evaluates the interaction between these PPIs and the antiplatelet drug clopidogrel. PPIs are often co-administered with dual antiplatelet therapy (aspirin and clopidogrel) to mitigate the risk of gastric bleeding. However, because both omeprazole and clopidogrel are metabolized by the CYP2C19 enzyme, there is a concern that PPIs may reduce the conversion of clopidogrel to its active form, potentially increasing the risk of cardiovascular events. The University of Florida study compares the timing of administration and the specific choice of PPI (omeprazole vs. pantoprazole) to determine if these factors influence the antiplatelet efficacy of clopidogrel.

Brand names

PrilosecProtonix

Other names

omeprazole and pantoprazole